These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 38945364

  • 1. Favourable effect of clavulanic acid on the minimum inhibitory concentrations of cefixime and ceftibuten in ESBL-producing Escherichia coli and Klebsiella pneumoniae.
    Martinez-Guerra BA, Xancal-Salvador LF, Esteban-Kenel V, Tello-Mercado AC, Bobadilla-Del-Valle M, Sifuentes-Osornio J, Ponce-de-Leon A, Gonzalez-Lara MF.
    J Glob Antimicrob Resist; 2024 Sep; 38():212-215. PubMed ID: 38945364
    [Abstract] [Full Text] [Related]

  • 2. In-vitro activity of oral third-generation cephalosporins plus clavulanate against ESBL-producing Enterobacterales isolates from the MERINO trial.
    Stewart AG, Bauer MJ, Butkiewicz D, Hinton A, Henderson A, Harris PNA, Paterson DL.
    Int J Antimicrob Agents; 2023 Aug; 62(2):106858. PubMed ID: 37211261
    [Abstract] [Full Text] [Related]

  • 3. Comparative susceptibility of clinical isolates producing extended spectrum beta-lactamases to ceftibuten: effect of large inocula.
    Medeiros AA, Crellin J.
    Pediatr Infect Dis J; 1997 Mar; 16(3 Suppl):S49-55. PubMed ID: 9076836
    [Abstract] [Full Text] [Related]

  • 4. Ceftibuten plus amoxicillin-clavulanic acid for oral treatment of urinary tract infections with ESBL producing E. coli and K. pneumoniae: a retrospective observational case-series.
    Cohen Stuart J, Leverstein-Van Hall M, Kortmann W, Verlind J, Mulder F, Scharringa J, Fluit A, Ekkelenkamp M.
    Eur J Clin Microbiol Infect Dis; 2018 Oct; 37(10):2021-2025. PubMed ID: 30117050
    [Abstract] [Full Text] [Related]

  • 5. In Vitro and In Vivo Activity of Amoxicillin-Clavulanate Combined with Ceftibuten or Cefpodoxime Against Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae.
    Gupta A, Malik S, Kaminski M, Landman D, Quale JM.
    Microb Drug Resist; 2022 Apr; 28(4):419-424. PubMed ID: 35451880
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Use of the cefepime-clavulanate ESBL Etest for detection of extended-spectrum beta-lactamases in AmpC co-producing bacteria.
    Mohanty S, Gaind R, Ranjan R, Deb M.
    J Infect Dev Ctries; 2009 Nov 21; 4(1):24-9. PubMed ID: 20130375
    [Abstract] [Full Text] [Related]

  • 8. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
    Kuzucu C, Yetkin F, Görgeç S, Ersoy Y.
    Mikrobiyol Bul; 2011 Jan 21; 45(1):28-35. PubMed ID: 21341156
    [Abstract] [Full Text] [Related]

  • 9. Prevalence and antimicrobial susceptibility of extended-spectrum beta lactamases-producing Escherichia coli and Klebsiella pneumoniae isolated in selected hospitals of Anyigba, Nigeria.
    Mofolorunsho KC, Ocheni HO, Aminu RF, Omatola CA, Olowonibi OO.
    Afr Health Sci; 2021 Jun 21; 21(2):505-512. PubMed ID: 34795702
    [Abstract] [Full Text] [Related]

  • 10. Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Bishara J, Livne G, Ashkenazi S, Levy I, Pitlik S, Ofir O, Lev B, Samra Z.
    Isr Med Assoc J; 2005 May 21; 7(5):298-301. PubMed ID: 15909461
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. In Vitro Activity of Cefotetan against ESBL-Producing Escherichia coli and Klebsiella pneumoniae Bloodstream Isolates from the MERINO Trial.
    Stewart AG, Cottrell K, Henderson A, Vemuri K, Bauer MJ, Paterson DL, Harris PNA.
    Microbiol Spectr; 2021 Sep 03; 9(1):e0022621. PubMed ID: 34232101
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
    Tsui K, Wong SS, Lin LC, Tsai CR, Chen LC, Huang CH.
    J Microbiol Immunol Infect; 2012 Jun 03; 45(3):193-9. PubMed ID: 22580086
    [Abstract] [Full Text] [Related]

  • 18. Dramatic rise in the proportion of ESBL-producing Escherichia coli and Klebsiella pneumoniae among clinical isolates identified in Canadian hospital laboratories from 2007 to 2016.
    Denisuik AJ, Karlowsky JA, Adam HJ, Baxter MR, Lagacé-Wiens PRS, Mulvey MR, Hoban DJ, Zhanel GG, Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD.
    J Antimicrob Chemother; 2019 Aug 01; 74(Suppl 4):iv64-iv71. PubMed ID: 31505647
    [Abstract] [Full Text] [Related]

  • 19. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: insights from a tertiary hospital in Southern Thailand.
    Romyasamit C, Sornsenee P, Kawila S, Saengsuwan P.
    Microbiol Spectr; 2024 Jul 02; 12(7):e0021324. PubMed ID: 38809095
    [Abstract] [Full Text] [Related]

  • 20. Extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae isolated in a rural hospital.
    Basak S, Mallick SK, Bose S.
    J Indian Med Assoc; 2009 Dec 02; 107(12):855-8. PubMed ID: 20509468
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.